PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J ECT. Author manuscript; available in PMC Sep 1, 2013.
Published in final edited form as:
PMCID: PMC3426617
NIHMSID: NIHMS363528
The Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Chadi G. Abdallah, Madonna Fasula, Ben Kelmendi, Gerard Sanacora, and Robert Ostroff
Department of Psychiatry and the Ribicoff Research Facilities, Yale University School of Medicine New Haven, CT USA 06519
Correspondence: Gerard Sanacora, M.D., Ph.D., CNRU at CMHC, 34 Park St., New Haven, CT 06519, United States., Tel.: +1 203 974 7535; fax: +1 203 974 7662., gerard.sanacora/at/yale.edu
Objectives
Studies now provide strong evidence that the NMDA receptor antagonist ketamine possesses rapidly acting antidepressant properties. This study aimed to determine if low dose ketamine could be used to expedite and augment the antidepressant effects of electroconvulsive therapy treatments in patients experiencing a severe depressive episode.
Methods
Subjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0.5 mg/kg) for anesthesia prior to each ECT session. Hamilton Depression Rating Scales (HDRS) were administered at baseline, and 24 – 72 h following the 1st and the 6th ECT sessions.
Results
ECT exerted a significant antidepressant effect in both groups (F(2,24) = 14.35, p < .001). However, there was no significant group effect or group-by-time interaction on HDRS scores. Additionally, post-hoc analyses of the time effect on HDRS showed no significant HDRS reduction after the 1st ECT session for either group.
Conclusions
The results of this pilot study suggest that ketamine, at a dose of 0.5 mg/kg, given just prior to ECT, did not enhance the antidepressant effect of ECT. Interestingly, the results further suggest that the co-administration of ketamine with a barbiturate anesthetic and ECT may attenuate the acute antidepressant effects of NMDA antagonist.
Keywords: ECT, Ketamine, rapid, antidepressant, barbiturate
Slightly over a decade ago, it was found that ketamine, an anesthetic agent with N-Methyl-D-aspartic acid receptor (NMDAR) antagonist properties, exerts a rapid and potent antidepressant effect in patients with severe treatment resistant depression 1. This finding has now been well replicated in several small pilot studies 213. The antidepressant effect exerted by ketamine in these preliminary studies is consistently evident within 4 hours of its administration, with response rates ranging between 50% and 90%, one to three days after a single injection of ketamine. This rapid antidepressant effect is in contrast to traditional monoamine-based antidepressants that take weeks to months to reach their full antidepressant effect 14, with response rates in the range of 40 – 50% 15. Accordingly, the newly found rapid robust antidepressant effect of ketamine has generated considerable enthusiasm in the field to integrate this valuable pharmacotherapy with other available treatment modalities in the management of severely ill patients.
Electroconvulsive therapy (ECT) is recognized as a highly effective treatment for unipolar and bipolar depression 16. ECT is generally considered to have a more rapid onset of action than standard antidepressant agents, but the limited data on the onset of ECT’s antidepressant action suggest that a range of 5–7 treatments (approximately 2 weeks) are required on average to obtain a significant reduction in symptom severity, varying some by position of lead placement and stimulus intensity 17. Therefore, it is logical to question whether co-administration of ketamine could expedite the antidepressant response of ECT. Interestingly, ketamine has been used in ECT anesthesia for decades 18, 19, with preliminary evidence suggesting that ketamine anesthesia in ECT may improve seizure duration relative to other anesthetic agents that are commonly used, and to minimize side effects, particularly cognitive impairment 20, 21. However, there is no evidence that the direct antidepressant effects of the drug were considered as a potential benefit to the use of drug in these early studies. More recently, a prospective study comparing ketamine (.86 mg/kg) to propofol (.94 mg/kg) for ECT anesthesia showed ketamine to be associated with an earlier antidepressant response over the first 2-weeks of ECT. However, the magnitude of the antidepressant effect did not differ between the two forms of anesthesia at weeks 3 and 4 22. This study showed longer seizure duration in the ketamine group during the 1st and 6th ECT session 22. Another recent retrospective study noticed a decrease in the number of total ECT sessions, lower depression severity scores, and higher cognitive ratings in patients who received S-ketamine (46.7mg) anesthesia as compared to thiopental (236mg)23.
In the current study, we sought to further investigate the potential ability of ketamine to accelerate the antidepressant effects of electroconvulsive therapy in patients suffering from a major depressive episode. Based on the doses used in the placebo controlled studies of ketamine, and the preclinical studies suggesting that low (sub-anesthetic) doses of ketamine had significantly different effects on brain physiology 24, 25 and behavior 26 than anesthetic doses, we chose to specifically examine the benefit of adding a low dose of ketamine (.5 mg/kg) to a standard anesthetic dose of thiopental.
Study design
Patients aged 18–65 experiencing a major depressive episode and scheduled to receive ECT treatment, and were able to provide voluntary consent, were recruited into this study. Participants met DSM-IV criteria for a diagnosis of either major depressive disorder (MDD) or bipolar disorder (BD) currently in a major depressive episode, as determined by a structured clinical interview 27. All participants provided written informed consent according to the Yale University School of Medicine human investigation committee approved study protocol. Exclusion criteria included a lifetime diagnosis of primary psychotic disorder, mental retardation, dementia, or mood disorder due to general medical condition. Patients with substance dependence or serious medical conditions were also excluded. The original pilot study plan was to randomize 40 patients into two treatment groups at a ratio of 1:1. However, a midterm analysis showed no difference between treatment groups and the study was stopped for futility. Thus, only 18 patients were enrolled into the two treatment groups.
Treatment
ECT was delivered either unilaterally or bilaterally via a SpECTrum 5000 Q (Mecta) as determined by the treating physician (RO), using the dose-titration method. In brief, seizure threshold was determined at the index treatment by gradual stimulus increase until seizure initiation was achieved. At the subsequent treatment the energy was increased by 50% for bilateral treatment and 5–6 fold for right unilateral treatment. As per our clinical protocol, energy would only be increased on subsequent treatments if there was failure to obtain adequate seizure morphology. ECT treatment was administered 3 times per week for the 2 weeks encompassing the study duration. EEG seizure duration was determined by two lead EEG and motor seizure duration was determined using the cuff method, observing foot movement.
The ketamine group (n = 9) received .5 mg/kg ketamine + 3.5 mg/kg thiopental I.V. push for anesthesia immediately prior to each ECT session. The control group (n = 9) received only thiopental (3.5 mg/kg) for anesthesia. Treatment-team members, including psychiatrists and nurses conducting the rating scales, were blinded to the treatment group –except for the anesthesiologist. Clinical assessment included Hamilton depression rating scale (HDRS25) 28 and Beck depression inventory (BDI) 29. HDRS25 was administered at baseline, and 24 – 72 h following the 1st and the 6th ECT sessions. BDI was administered at baseline and after the 6th ECT session. ECT measures were recorded for each session.
Statistical analysis
Prior to conducting each analysis, the distribution of outcome measures was examined using Kolmogorov-Smirnov test statistics. The Mann-Whitney U test was used for skewed distributions. Demographics and clinical measures were compared among groups using Chi square or independent t-test. General Linear Model (GLM) repeated-measures was conducted on HDRS25 as the dependent variable, with time of assessment (baseline, after 1st ECT & 6th ECT) as the within-subject factor, and treatment group (Ketamine vs. control) as the between-subjects factor. Post-hoc analyses of pairwise comparisons of estimated marginal means used Bonferroni adjustment for multiple comparisons. Similar analysis was employed for BDI as the dependent variable. Average EEG and motor seizure durations across all sessions were compared among groups. Given that the duration measures were not normally distributed, Mann-Whitney U test was used to compare treatment groups (ketamine vs. control).
Demographic characteristics, revealing a larger percentage of MDD subjects concomitantly using antidepressant medications in the ketamine group and larger percentage of BD subjects concomitantly using mood stabilizers in the control group but similar baseline depression severity ratings, are reported in Table 1. One patient in each group exited the study before any post-treatment follow-up. One subject in each group also exited the study prior to the 6th treatment.
Table 1
Table 1
Demographics and Clinical Data
Both treatment conditions were associated with symptom improvement (Table 2). GLM repeated-measures showed a strong main time effect on HDRS25 (F(2,24) = 14.35, p < .001), reflecting an antidepressant effect in both groups. Partial Eta Squared effect size was .55 (a medium sized effect). However, there was no significant difference among groups (ketamine vs. control) (F(1,12) = .09, p = .76) or group-by-time interaction (F(2,24) = .66, p = .52), indicating that sub-anesthetic doses of ketamine did not enhance the antidepressant effect of ECT. Post-hoc analyses of the time effect on HDRS25, using Bonferroni adjustment for multiple comparisons, showed no significant HDRS25 reduction after the 1st ECT session (p = .074), showing no rapid antidepressant effect in both groups. The antidepressant effect in both groups only reached significance after the 6th ECT session (p = .001) (see Fig. 1). Similar GLM repeated-measure analysis showed main time effect on BDI (F(1,12) = 13.15, p = .003). Yet, there was no treatment group (ketamine vs. control) effect (F(1,12) = .03, p = .85) or treatment-by-time interaction effect (F(2,24) = 2.04, p = .18).
Table 2
Table 2
Clinical Outcomes
Figure 1
Figure 1
Hamilton Depression Rating Scale Improvement Over the Treatment Period
Examining the response rate (≥ 50% reduction on HDRS25) among groups, we found no responders in the ketamine group following the 1st ECT treatment. At the same time point, there was 1 (13%) responder in the control group. After the 6th ECT, we found 1 (13%) responder in the ketamine group and 3 (38%) responders in the control. Chi-Square test, conducted at both time points, showed no statistically significant difference in response rate between groups (p > .20). GLM analyses were repeated while including diagnosis (MDD vs. bipolar depression) and ECT lead placement (unilateral vs. bilateral). These analyses showed similar findings of significant antidepressant effect (p < .001), but no effect for groups (p > .6), diagnosis (p > .3), ECT lead placement (p > .8), or interaction (p > .5). Significance was not changed when medication status was included in the model (data not shown).
EEG and motor seizure durations are reported in Table 3. There is a suggestion that ketamine augmentation may be associated with an increased duration of motor seizure and a weak trend toward EEG seizure duration lengthening. No major adverse effects were observed in this cohort during the 2 weeks of ECT treatment. Minimal transient side effects reported by both groups included nausea, headaches, disorientation, and muscle pain.
Table 3
Table 3
Seizure and Convulsion Durations
Although this by no means can be considered a definitive study, we found no evidence suggesting ketamine at .5 mg/kg administered with thiopental anesthesia for ECT facilitated a more rapid antidepressant response. There were no statistically significant or clinically meaningful differences in depression severity scores or likelihood of response between the ketamine and control groups after the first and 6th ECT treatments. In fact, the control (thiopental only) group showed a slightly greater numerical reduction in depression severity ratings at both time points. It is difficult to draw any firm conclusions regarding the differences between the two treatment groups from this small study as there were potentially important differences in the breakdown of diagnoses and concomitant medications between the two groups, in addition to the varied lead placement. However, considering the existing study protocol design for this study, we determined that it was futile to continue this preliminary study.
Perhaps the most interesting finding to come from this study was the fact that within the ketamine group, we did not observe the robust rapid antidepressant response that has been reported in several previous studies. The current study found no subjects to meet response criteria one day following ketamine administration. This is in stark contrast to the highly consistent reports of 50–90% response rates in the days immediately following a single dose of 0.5 mg/kg ketamine 1, 2, 4, 5, 9, 30. There are several factors that may account for this surprising result. First, it is possible that this study, selectively enrolling subjects recommended for ECT, included a more severe and treatment resistant cohort of subjects. However, considering the level of subject severity and treatment resistance reported in the previous studies 1, 4, and the finding that ECT non-response did not have a major impact on ketamine treatment outcome 7, this does not seem a likely explanation. Second, it is possible that the change in the mode of administration (given IV push instead of IV infusion) altered the antidepressant efficacy of the treatment. Again however, there is evidence from at least one open-label study 30 suggesting that an IV push, albeit 0.25 mg/kg, was highly effective in producing the rapid antidepressant response. Skeptics of the rapid antidepressant properties of ketamine may suggest a third option; since ketamine was co-administered with an anesthetic agent, both the researchers and the subjects were truly blinded to the treatment. However, there is evidence from Kudoh et al. study showing that ketamine co-administered with fentanyl and propofol anesthesia for orthopedic surgery still appeared to have potent rapid antidepressant-like properties 31. A fourth potential explanation for the discrepant findings is that the ECT treatment itself blocked or attenuated the antidepressant effects of ketamine. Although studies by Okamoto and Kranaster, where ketamine was used as the sole anesthetic agent, did suggest some added effects of ketamine on mood 22, 23. However, intriguingly, the literature remains devoid of any report of rapid (within 1–3 days) and potent (response rate 50–90%) antidepressant effect following the use of ketamine in ECT. One case-report noticed a rapid antidepressant effect following the administration of intramuscular ketamine (1.5 mg/kg) and one ECT session in a patient with major depression 32. However, ketamine was injected one hour prior to ECT in this study, raising the question if ketamine already exerted its antidepressant effect before the ECT session.
An additional possible explanation for the failure to see the rapid ketamine-induced antidepressant effect in this study is the fact that ketamine was co-administered with thiopental, a barbiturate anesthetic agent. It is conceivable that the thiopental effects interfere with ketamine’s mechanism of antidepressant action. Barbiturates are believed to exert their main physiological effect by potentiating the effects of γ-Aminobutyric acid (GABA) at the GABAA receptor through their affinity for the alpha subunit of the receptor 33. In addition to this GABAergic effect, barbiturates have also been shown to block the signaling through the AMPA subtype of glutamate receptor 34. Considering these effects of thiopental on GABAergic and glutamatergic neurotransmission, it is possible that it may have resulted in an attenuation of ketamine’s antidepressant effects. Several recent preclinical studies have demonstrated the necessity of a “glutamate surge” and the accompanying AMPA activation in generating the antidepressant–like response of ketamine and other NMDA antagonists 26, 35, 36. It is hypothesized that ketamine increases glutamate release by selectively inhibiting GABAergic neurons and thus removing the inhibition on pyramidal neurons in the cortex 37. So either the inhibition of glutamate release via activation of GABAA receptors by thiopental or the direct inhibition of AMPA receptors by thiopental may have antagonized the antidepressant effect of ketamine when administered concomitantly. The other two recent studies examining the use of ketamine anesthesia in the ECT setting did not co-administer an additional anesthetic with the treatment 22, 23. The Kudoh study, examining the effects of sub-anesthetic ketamine combined with an anesthetic cocktail, used propofol and fentanyl and not a barbiturate anesthetic 31.
Lastly, the finding of increased motor seizure duration and possible increase in seizure duration is of some clinical interest. There has been speculation that ketamine is clinically useful in subjects with high seizure thresholds 38, 39. Preclinical studies have shown ketamine to be associated with increased seizure duration 40. However, the literature in humans is mixed with regards to the effect of ketamine on seizure duration 41. In our study, adding a low dose (.5 mg/kg) of ketamine to thiopental we do see some evidence suggesting an effect on seizure duration. However, considering the difference in concomitant medications used by the two groups this needs to be confirmed.
In summary, although the literature provides very strong evidence of ketamine’s rapid and robust antidepressant effects in severely depressed patients, these preliminary findings failed to support the hypothesis that low doses of ketamine (.5 mg/kg), in addition to thiopental anesthesia, can expedite and enhance the rapid antidepressant effects of ECT. In fact, ECT setting appears to attenuate the rapid antidepressant effect of ketamine. These findings, that appear to be somewhat at odds with existing case reports suggesting ketamine anesthesia my hasten the ECT response, may be explained in part by the fact that ketamine was co-administered with a barbiturate anesthetic agent in this study. It is quite possible that different doses, timing and routes of ketamine administration may produce different findings. Additionally, the sole use of ketamine as the anesthetic agent or with a different class of co-administered anesthetic could also have different effects on the treatment response. Future studies investigating the potential benefits of ketamine augmentation to ECT should consider the effects of ketamine dose, timing and concomitant medications in the study design.
Footnotes
Conflict of Interest and Source of Funding:
This work was supported by the State of Connecticut, Department of Mental Health and Addiction Services through its support for the Connecticut Mental Health Center. National Institute of Mental Health (K02 MH076222-04)(GS), and National Institute on Drug Abuse (T32-DA022975)(CGA).
G.S. has received consulting fees from Abbott, AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Evotec, Eli Lilly & Co., Hoffman La-Roche, Johnson & Johnson, Novartis and Novum Pharmaceuticals over the past 24 months. He has also received additional grant support from AstraZeneca, Bristol-Myers Squibb, Hoffman La-Roche, Merck & Co. and Sepracor Inc. over the past 24 months. In addition, he is a co-inventor on a filed patent application by Yale University (PCTWO06108055A1). C.G.A., M.F., B.K. and R.O. report no competing financial interests.
1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. [PubMed]
2. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. [PMC free article] [PubMed]
3. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191(2):122–127. [PMC free article] [PubMed]
4. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. [PubMed]
5. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145. [PubMed]
6. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–1611. [PMC free article] [PubMed]
7. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1155–1159. [PMC free article] [PubMed]
8. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70(12):1662–1666. [PMC free article] [PubMed]
9. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82. [PubMed]
10. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65(2):181–184. [PMC free article] [PubMed]
11. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–526. [PMC free article] [PubMed]
12. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65(4):289–295. [PMC free article] [PubMed]
13. Salvadore G, Cornwell BR, Sambataro F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010;35(7):1415–1422. [PMC free article] [PubMed]
14. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29(3):566–579. [PubMed]
15. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. [PubMed]
16. Weiner RD. American Psychiatric Association Committee on Electroconvulsive Therapy. The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging: A task force report of the American Psychiatric Association. 2. Amer Psychiatric Pub Inc; 2001. p. 355.
17. Nobler MS, Sackeim HA, Moeller JR, et al. Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods. Convuls Ther. 1997;13(4):208–221. [PubMed]
18. Green CD. Ketamine as an anaesthetic for ECT. The British journal of psychiatry : the journal of mental science. 1973;122(566):123–124. [PubMed]
19. Brewer CL, Davidson JR, Hereward S. Ketamine (“Ketalar”): a safer anaesthetic for ECT. The British journal of psychiatry : the journal of mental science. 1972;120(559):679–680. [PubMed]
20. Krystal AD, Weiner RD, Dean MD, et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. The Journal of Neuropsychiatry and Clinical Neurosciences. 2003;15(1):27–34. [PubMed]
21. McDaniel WW, Sahota AK, Vyas BV, et al. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. The journal of ECT. 2006;22(2):103–106. [PubMed]
22. Okamoto N, Nakai T, Sakamoto K, et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J Ect. 2010;26(3):223–227. [PubMed]
23. Kranaster L, Kammerer-Ciernioch J, Hoyer C, et al. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011 [PubMed]
24. Duncan GE, Moy SS, Knapp DJ, et al. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Research. 1998;787(2):181–190. [PubMed]
25. Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921–2927. [PubMed]
26. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. [PMC free article] [PubMed]
27. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P. Version 2.0. Biometric Research, New York State Psychiatric Institute; New York: 1995.
28. Hamilton M. Standardised assessment and recording of depressive symptoms. Psychiatr Neurol Neurochir. 1969;72(2):201–205. [PubMed]
29. Beck Robert A, Aaron T. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988;8(1):77–100.
30. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011:1–5. [PubMed]
31. Kudoh A, Takahira Y, Katagai H, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95(1):114–118. table of contents. [PubMed]
32. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J Ect. 2007;23 (1):23–25. [PubMed]
33. Ho IK, Harris RA. Mechanism of action of barbiturates. Annu Rev Pharmacol Toxicol. 1981;21:83–111. [PubMed]
34. Kamiya Y, Andoh T, Furuya R, et al. Comparison of the effects of convulsant and depressant barbiturate stereoisomers on AMPA-type glutamate receptors. Anesthesiology. 1999;90(6):1704–1713. [PubMed]
35. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011;224(1):107–111. [PubMed]
36. Maeng S, Zarate CA, Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349–352. [PubMed]
37. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27(43):11496–11500. [PMC free article] [PubMed]
38. Loo C, Simpson B, MacPherson R. Augmentation strategies in electroconvulsive therapy. J Ect. 2010;26(3):202–207. [PubMed]
39. Loo CK, Kaill A, Paton P, et al. The difficult-to-treat electroconvulsive therapy patient - Strategies for augmenting outcomes. Journal of Affective Disorders. 2010;124(3):219–227. [PubMed]
40. Lunn RJ, Savageau MM, Beatty WW, et al. Anesthetics and electroconvulsive therapy seizure duration: implications for therapy from a rat model. Biological Psychiatry. 1981;16(12):1163–1175. [PubMed]
41. Rasmussen KG, Jarvis MR, Zorumski CF. Ketamine anesthesia in electroconvulsive therapy. Convuls Ther. 1996;12(4):217–223. [PubMed]